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Abstract The cellular and molecular effects of the pro-
teasome inhibitor—bortezomib—on breast cancer cells are
as yet poorly characterised. Bortezomib selectively induces
apoptosis in some cancer cells. However, the nature of its
selectivity remains unknown. Previously, we demonstrated
that: there was no effect of bortezomib action on apoptosis
and a time-dependent increase in senescence of human skin
fibroblasts. The study presented here provides novel
information on cellular effects of bortezomib in breast
cancer cells line MDA-MB-231. Our findings demonstrated
that in contrast to normal fibroblasts, bortezomib treatment
evoked a strong effect on apoptosis in breast cancer cells
incubated in hypoxic and normoxic conditions. We
observed a time-dependent increase up to 70 % in apop-
tosis of MDA-MB-231 cells in hypoxic and normoxic
conditions. There was no effect of bortezomib action on
senescence of these cells. We suggest that bortezomib may
be candidates for further evaluation as chemotherapeutic
agents for human breast cancer.
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Introduction
The endoplasmic reticulum (ER) is a vital organelle that
performs important cellular functions, including the post-
translational processing, folding, and trafficking of newly
synthesized proteins. A variety of chemicals and adverse
environmental conditions, such as hypoxia or nutrient depri-
vation, can disturb the normal function of this organelle,
causing ER stress associated with the accumulation of mal-
folded protein aggregates [1, 2]. The unfolded protein
response (UPR) occurs as an adaptive compensatory reaction
to ER stress, characterised by the upregulated synthesis of ER
chaperone proteins, the attenuation of protein translation, and
the activation of an ER-associated degradation system [2, 3].
In the ER-associated degradation pathway, malfolded or
denatured proteins are exported from the ER lumen to the
cytosol, and are then degraded by the proteasome [4]. The 26S
proteasome is a large multi-subunit complex (2,000 kDa)
composed of a central 20S catalytic core particle (20S pro-
teasome) and two 19S subunits that recognize ubiquitinated
proteins [5]. Bortezomib (velcade), formerly known as PS-
341 is a competitive inhibitor of 20S proteasome activity in
whole cells. The chemical name for bortezomib is [(1R)-3-
methyl-1-({(2S)-3-phenyl-2-[(pyrazin-2-ylcarbonyl)amino]pro-
panoyl}amino)-butyl] boronic acid. It is used in the treatment of
multiple myeloma and some forms of non-Hodgkin’s lymphoma
[5, 6]. Bortezomib inhibition of the proteolytic activity of the 20S
proteasome has been shown to induce pro-apoptotic ER stress
and inhibit proteasome degradation of nuclear factor-kB (NF-
jB) inhibitor in the cancer cell [5, 6].
The inhibition of the proteasome results in many toxic
effects, including the accumulation of unfolded and dam-
aged proteins [7–9]. In response to proteasome inhibition,
the cell induces specific protective mechanisms, including
the unfolded protein response [7], autophagy [10, 11].
However, conditions of excessive ER stress may led to
apoptosis [7, 12]. Apoptosis plays a major role in the
control of cancer development. In fact, cells encounter
multiple apoptotic stimuli during cancer progression,
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including nutrient deprivation or hypoxia. Accordingly, it
has been suggested that the well-documented anti-apopto-
tic potential of chaperones may play a critical role in the
suppression of apoptosis in cancer cells [13, 14]. Recently,
attention has shifted towards a novel role of cell senescence
in the control of cancer development, and with this shift
our view on the role of chaperones in cancer has also
evolved towards appreciation of their major role in the
regulation of senescence [15].
Senescence can be generally characterised as a cellular
stress response. It is a signal transduction process that leads to
an irreversible growth arrest of cells in the G1 cell cycle phase
[16]. Our knowledge about cell senescence occurring in vivo
and, most importantly, as a desired outcome of cancer treat-
ment, is very limited and can still be viewed as an emerging
field of study. The term senescence was originally applied to
the irreversible growth arrest of cells after prolonged prolif-
eration under in vitro cell culture conditions. Now it has been
extended to the irreversible proliferation arrest of cells caused
by various stresses, including oxidative damage, telomere
dysfunction, DNA damage and oncogene-induced senes-
cence as well [17–19]. Tumour cells are exposed to many
different external as well as internal sources of stress; there-
fore, the induction of senescence constitutes an important
block to tumour progression [16]. Senescence is a potent anti-
carcinogenic programme and the process of neoplastic
transformation involves a series of events that allow cells to
bypass senescence by inactivation of senescence-associated
pathways. Still, many tumour cells have retained the capacity
to senesce in response to external stress stimuli. Most con-
ventional anti-cancer therapies activate DNA damage sig-
nalling pathways, thus aiming to induce primarily apoptotic
cell death, but often the treated cells do not die by apoptosis
but rather undergo growth arrest or senescence. It is not fully
understood currently which specific signals cause cells to
undergo either senescence or initiate apoptosis [16]. Senes-
cence runs in parallel with an accumulation of damaged
proteins in the cell. The attenuation of molecular chaperone
inducibility and the simultaneous accumulation of damaged
proteins raise the possibility that preservation of protein ho-
moeostasis is a major determinant of the occurrence and
duration of cellular senescence [13].
The breast cancer represents a major problem due to both
high incidence rate and still unsatisfactory treatment results
[20]. The studies were performed on estrogen-independent
MDA-MB-231 cells, expressing only b estrogen receptor.
Theses cells are highly invasive and metastatic in rodent
models [21]. Inhibition of proteasomal degradation system
may represent a target in pharmacotherapy of estrogen
receptor-negative breast cancer MDA-MB-231 cells. The
cellular and molecular effects of the proteasome inhibitor—
bortezomib—on breast cancer cells line—MDA-MB-231
are as yet poorly characterised. We decided to study the
effect of bortezomib on apoptosis and senescence of breast
cancer cells line—MDA-MB-231 incubated in hypoxic and
normoxic conditions. We investigated the effect of bort-
ezomib on the activity of senescence marker—SA-b-galac-
tosidase and induction of ORP150 chaperon in cell line—
MDA-MB-231 and its correlation with apoptosis of these
cells incubated in hypoxic and normoxic conditions.
Materials and methods
Reagents
Dulbecco’s modified Eagle’s medium (DMEM) containing
glucose at 4.5 mg/ml (25 mM) with Glutamax, penicillin,
streptomycin and trypsin–EDTA were provided by Invit-
rogen (San Diego, USA), passive lysis buffer by Promega
(Madison, USA), FBS Gold by Gibco (San Diego, USA),
BCA Protein Assay Kit by Thermo Scientific (Rockford,
USA), PE Annexin V Apoptosis Detection Kit I by BD
PharmingenTM (CA, USA), Senescence Detection Kit by
bioVision (CA, USA), Sigma-Fast BCIP/NBT reagent by
Sigma (St Louis, MO, USA), monoclonal (mouse) anti-
human ORP150 antibody by IBL (Gunma, Japan), mono-
clonal (mouse) anti-HIF-1a antibody by BD Biosciences
(CA, USA), and alkaline phosphatase-labelled anti-mouse
immunoglobulin G by Rockland (PA, USA), precision plus
protein standards by Bio-Rad Laboratories (USA).
Cell cultures
Human breast cancer cell line MDA-MB-231 and human
skin fibroblasts (CRL1474) were obtained from American
Type Culture Collection (ATCC). Cells were maintained
in high-glucose DMEM supplemented with 10% heat-
inactivated foetal bovine serum GOLD (FBS GOLD),
2 mM L-glutamine, penicillin (100 U/ml) and streptomy-
cin (100 lg/ml). Cells were cultured in Falcon flasks (BD)
in a 5 % CO2 incubator (Galaxy S?; New Brunswick), at
37 C. Subconfluent cultures were detached with 0.05 %
trypsin and 0.02 % EDTA in calcium-free phosphate-
buffered saline (PBS) and counted in a Scepter cell counter
(Millipore).
Cell viability
Cell viability was measured according to the method of
Carmichael [22] using 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT). Briefly, cells were
seeded in 24-well plate at a density of 100,000 per well.
Confluent cells, cultured for 12 h, 24 h and 48 h in
normoxic conditions in the concentration from 25 to
1,000 nmol/l, were washed three times with PBS and then
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incubated with 1 ml of MTT solution (0.25 mg/ml in PBS)
for 4 h, at 37 C in 5 % CO2 in an incubator. The medium
was removed and 1 ml of 0.1 mol/l HCl in absolute iso-
propanol was added. Absorbance of converted dye in living
cells was measured at wavelength of 570 nm. The viability
of MDA-MB-231cells and human skin fibroblasts cultured
in hypoxic conditions was calculated as percentage of
control cells, incubated in normoxia. All the experiments
were done in duplicate in at least three cultures.
Induction of hypoxia in cell cultures
The cells (5 9 105 in 2 ml of medium) were seeded in six-well
plates and incubated until they achieved confluence. The high-
glucose DMEM was removed and replaced with 2 ml of the
same fresh medium with various concentrations of bortezo-
mib. Control cell cultures were kept in normoxic conditions
whereas the test cells were incubated in hypoxic conditions.
Hypoxia was evoked by 12 h, 24 h and 48-h incubation of cells
in atmosphere containing a reduced to 1 % oxygen concen-
tration in hypoxia chamber (Galaxy 170R; New Brunswick an
Eppendorf company). After incubation the culture media were
removed, the cell layers were washed with PBS and submitted
to the action of lysis buffer for determination of ORP150/
GRP170, HIF-1a expression and protein concentration. It
allowed the separation of cells and extracellular matrix from
the bottom of culture vessels and their suspension in the buffer.
The cells incubated on six-well plates were detached with
trypsin and analyzed by flow cytometry method.
Detection of apoptosis
The cells (5 9 105 in 2 ml of medium) were seeded in six-
well plates and incubated until they achieved confluence.
The MDA-MB-231 cells were incubated in the high-glu-
cose DMEM in hypoxic and normoxic conditions with 25
or 50 nmol/l of bortezomib. The incubation was continued
for 12 h, 24 h and 48 h. Apoptosis was evaluated by flow
cytometry on FACSCanto II cytometer (Becton Dickin-
son). The cells were trypsinised and resuspended in
DMEM and then in binding buffer. Cells were stained with
FITC Annexin V and PI for 15 min at room temperature in
the dark following the manufacturer’s instructions (FITC
Annnexin V apoptosis detection Kit I). Data were analyzed
with FACSDiva software and dead cells were excluded
based on forward- and side-scatter parameters.
Detection of SA-b-galactosidase expression
For cytochemical detection of SA-b-galactosidase staining
5 9 105 cells in 2 ml of growth medium were seeded in Petri
dishes (9.5 cm2) and incubated for 24 h in the high glucose
DMEM. In these conditions they reached 70–80 %
confluence. Cells were incubated in the high-glucose DMEM
in hypoxic and normoxic conditions with 25 or 50 nmol/l of
bortezomib. The incubation was continued for 12 h, 24 h and
48 h. After this time the medium was removed and the cell
layers ware washed with 2 ml of PBS. SA-b-galactosidase-
positive cells were detected using Senescence Detection Kit
(bioVision). Briefly, the cells were fixed with 1 ml of Fixative
Solution for 15 min at room temperature and washed with
2 ml of PBS. After washing Staining Solutions Mix was
added [940 ll of Staining Solution, 10 ll of Staining Sup-
plement and 10 ll of 20 mg/ml 5-bromo-4-chloro-3-indolyl-
b-D-galactopyranoside (X-gal)] at 20 mg/ml concentration,
at pH 6.0 which ensures that nonsenescent cells remain
unstained. The cells were incubated for 12 h at 37 C. After
incubation the cells were washed with PBS and stained cul-
tures were photographed under an inverted microscope
(Olympus CKX 41) at 200-fold magnification. The percent-
age of SA-b-galactosidase-positive cells was determined by
counting the number of blue cells under bright-field illumi-
nation, and then the total number of cells in the same field
under phase contrast.
Sodium dodecyl sulphate-polyacrylamide gel
electrophoresis (SDS-PAGE)
Cells were washed with cold PBS and solubilised in 100 ll
of passive lysis buffer per well. The lysates were centri-
fuged for 10 min, at 12,0009g, at 4 C. Samples of lysates
containing 20 lg of protein were subjected to SDS-PAGE,
as described by Laemmli [23]. The Bio-Rad precision plus
protein standards were used. Electrophoresis was run for
40–45 min. In each experiment 7.5 % polyacrylamide gel
and constant current (25 mA) were used.
Immunoblotting
The proteins were transferred to nitrocellulose membranes
and then pretreated for 2 h with Tris-buffered saline (TBS)
containing 0.05 % Tween 20 (TBS-T) and 5 % non-fat dry
milk, at room temperature. Membranes were probed for
16 h with a mixture containing monoclonal (mouse) anti-
human ORP150 antibody (1: 100) or monoclonal (mouse)
anti-human HIF-1a (1: 500) in 5 % dried milk in TBS-T, at
4 C. Then the alkaline phosphatase conjugated antibody
against mouse IgG (whole molecule) was added at a
1:2,500 dilution in TBS-T for 1 h with slow shaking. The
nitrocellulose was washed with TBS-T (five times for
5 min) and exposed to Sigma-Fast BCIP/NBT reagent.
Protein assay
Protein concentration in cell lysates was determined by the
method of Smith [24] using BCA Protein Assay Kit
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(Thermo Scientific, USA). Bovine serum albumin was used
as a standard.
Statistical analysis
Mean values from three independent experiments ± stan-
dard deviations (SD) were calculated. Statistical analysis
was performed using Student’s t test.
Results
The effect of bortezomib on viability of MDA-MB-
231 cell line
The antiproliferative effect of bortezomib was assessed by
MTT method in MDA-MB-231 cells in comparison to
normal fibroblasts cultured with increasing concentrations
of bortezomib for periods of 12 h, 24 h or 48 h. Fig-
ure 1A shows that bortezomib, in the concentration from
25 to 1,000 nmol/l, caused a time-dependent and dose-
dependent strong reduction in cell viability of the MDA-
MB-231 cells. An evident inhibition in cell viability was
observed as early as 12 h. Moreover, IC50 was achieved
after incubation for 12 h, 24 h and 48 h of MDA-MB-231
cells only with 25 and 50 nmol/l of bortezomib. In cells
treated with higher concentrations of bortezomib, the
effect on cell viability was markedly more pronounced
(Fig. 1A).
In contrast to tumour MDA-MB-231 cells we observed
only weak reduction in viability of normal skin fibroblasts
using bortezomib in the concentration from 25 to
1,000 nmol/l (Fig. 1B). Moreover, IC50 was achieved after
12 h, 24 h and 48 h incubation of fibroblasts with all the
tested concentrations of bortezomib (Fig. 1B).
Altogether these results show that bortezomib exhibits a
time-dependent and dose-dependent evident inhibition in
cell viability of breast cancer MDA-MB 231 cells, in
contrast to normal fibroblasts demonstrating high resistance
to this inhibitor.
Detection of HIF-1a in MDA-MB-231 cells submitted
to hypoxia
We also characterised the expression of HIF-1a, a bio-
chemical marker of hypoxia. Figure 2 shows that cells
grown in normoxic conditions (for 12 h—lane 1; for
24 h—lane 3; for 48 h—lane 5) did not demonstrate or
demonstrate weak expression of HIF-1a. In contrast, those
cells incubated in hypoxic conditions demonstrated an
intense expression of HIF-1a after 12, 24 and 48 h (Fig. 2,
lane 2, 4 and 6). The expression of HIF-1a after 12 h (lane
2) was higher in comparison to 24 h or 48 h (lane 4 and 6).
The effect of bortezomib on apoptosis of MDA-MB-
231 cells
Next we investigated whether bortezomib toxicity was due
to the induction of apoptosis. Figure 3 shows the per cent of
apoptotic MDA-MB-231 cells incubated for 12 h, 24 h and
48 h in normoxic and hypoxic conditions with 25 or
50 nmol/l of bortezomib. Cells incubated for 12 h both in
hypoxic and normoxic conditions with 25 or 50 nmol/l of
Fig. 1 The viability of breast cancer cells treated with different
concentrations of bortezomib for 12 h, 24 h and 48 h. The results are
mean for pooled triplicate values from three independent experiments.
Significant alterations are expressed relative to controls and marked
with asterisks. Statistical significance was considered if *p \ 0.05
Fig. 2 Western immunoblot analysis of HIF-1a synthesized by breast
cancer cells has been presented. The cells were incubated in normoxic
and hypoxic conditions for 12 h, 24 h and 48 h. Samples containing
30 lg of protein were submitted to electrophoresis and immunoblot-
ting. A representative Western immunoblot is presented. The
molecular mass (MM) of the precision plus protein standards are
indicated on the left sides of the lane
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bortezomib did not demonstrate statistically significant
differences in comparison to control cells, incubated without
bortezomib. In the cells incubated for 24 h and 48 h in
hypoxic and normoxic conditions with bortezomib we
observed a time-dependent increase in apoptosis of MDA-
MB-231 cells (Fig. 3). The per cent of apoptotic cells after
24 h and 48 h of incubation was threefold higher for
25 nmol/l of bortezomib and fourfold higher for 50 nmol/l
of bortezomib, in comparison to control cells. Incubation of
MDA-MB-231 cells for 48 h with 50 nmol/l of bortezomib
resulted in an increase of apoptosis—up to 70%. The per
cent of apoptotic cells in the breast cancer cells cultured in
hypoxia did not change significantly in comparison to the
same cells incubated in normoxia, independently on incu-
bation time and concentration of bortezomib (Fig. 3).
The effect of bortezomib on SA-b-galactosidase
expression
The induction of senescence constitutes an important block
to tumour progression. We therefore investigated whether
bortezomib induced biomarker of cellular senescence. The
SA-b-galactosidase expression was determined with the
use of chromogenic X-gal substrate. Normal cells showing
traits of division do not undergo reaction with this sub-
strate. However, the cells with evoked cell division
blockade become intensely blue stained. Higher SA-b-
galactosidase expression in cytoplasm caused the intensi-
fication of this reaction.
Figure 4 shows the per cent of SA-b-galactosidase-
positive MDA-MB-231cells incubated for 12 h, 24 h or 48 h
in normoxic and hypoxic conditions with 25 or 50 nmol/l of
bortezomib. The per cent of SA-b-galactosidase-positive
MDA-MB-231 cells did not change significantly both in
hypoxia and normoxia (Fig. 4), independently on incubation
time and concentration of bortezomib. Moreover, no sig-
nificant differences between cultures incubated with various
concentrations of bortezomib in comparison to control were
observed (Fig. 4).
Figure 5 displays a representative photographs of posi-
tive for SA-b-galactosidase staining MDA-MB-231 cells
incubated for 12 h, 24 h and 48 h in normoxic and hypoxic
conditions with 25 or 50 nmol/l of bortezomib. The amount
of SA-b-galactosidase-positive MDA-MB-231cells did not
Fig. 3 The effect of bortezomib on apoptosis of breast cancer cells.
The cells were incubated in normoxic and hypoxic conditions for 12
h, 24 h and 48 h. Mean values from three independent experiments
±SD are presented. Significant alterations are expressed relative to
controls and marked with asterisks. Statistical significance was
considered if *p \ 0.05
Fig. 4 The effect of bortezomib on percentage of SA-b-galactosidase
expression in MDA-MB-231 cells. The cells were incubated for 12 h,
24 h and 48 h in normoxic and hypoxic conditions. Mean values from
three independent experiments ±SD are presented
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Fig. 5 Cytochemical staining
for SA-b-galactosidase in
MDA-MB-231 cells. The cells
were incubated for 12 h, 24 h
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change significantly both in hypoxia and normoxia, inde-
pendently on incubation time and concentration of bort-
ezomib (Fig. 5). Moreover, no significant differences
between cultures incubated with 25 or 50 nmol/l of bort-
ezomib in comparison to control were observed (Fig. 5).
The effect of bortezomib on the expression of ORP150/
GRP170
Overexpression of Hsp70 chaperons (ORP150 belongs to
this family) may protect cancer cells against entering the
apoptotic pathway. Figure 6 shows the expression of
ORP150, and its glycosylated form GRP170, in MDA-MB-
231 incubated in normoxic and hypoxic conditions with 25
and 50 nmol/l of bortezomib. We observed induction of
ORP150 expression in hypoxic conditions only.
The expression of GRP170 in MDA-MB-231 was
observed in cultures incubated in normoxic conditions for
12 h, 24 h and 48 h, independently on concentration of
bortezomib (Fig. 6; lanes 1–3). It is of interest that MDA-
MB-231 cells incubated in normoxia did not express
ORP150 (Fig. 6; lanes 1–3). The induction of ORP150
expression was observed in hypoxic conditions in MDA-
MB-231 incubated for 12 h, independently on
concentration of bortezomib (Fig. 6; lanes 4–6). Prolon-
gation of incubation up to 24 h and 48 h resulted in
intensification of ORP150 expression. Moreover, a slight
expression of GRP170 was observed in MDA-MB-231cells
incubated in hypoxic conditions (Fig. 6; lanes 4–6).
Discussion
The 26S proteasome inhibitor, bortezomib, selectively
induces apoptosis in some cancer cells. However, the nat-
ure of its selectivity remains unknown. The work presented
here provides novel information on cellular effects of
bortezomib in MDA-MB-231 breast cancer cell line. We
observed that bortezomib reduces cell viability of the tested
cultures in a concentration and time-dependent manner.
Our results demonstrate the efficient induction of apoptosis
by proteasome inhibitor bortezomib in the human MDA-
MB-231 breast cancer cell line. We observed a time-
dependent increase, up to 70 %, in apoptosis of MDA-MB-
231 cells. We demonstrated that the per cent of apoptotic
cells in the breast cancer cells cultured in hypoxia did not
change significantly in comparison to the same cells
incubated in normoxia, independently on incubation time
and concentration of bortezomib. There was no effect of
bortezomib action on senescence of breast cancer cells. In
contrast to breast cancer cells we found that there was no
effect of bortezomib action on apoptosis and a time-
dependent increase in senescence of normal skin fibro-
blasts. Our previous study shown that: bortezomib caused a
time-dependent increase in senescence of normal fibro-
blasts, especially of these incubated in hypoxic conditions.
The SA-b-galactosidase expression raised over 40 % after
24 h and over 70 % after 48 h of incubation [25].
The maintenance of protein homoeostasis in cell requires
the activities of chaperones and the ubiquitin–proteasome
system, which together serve to inactivate and degrade
misfolded proteins. When proteins are not folded properly,
they are directed to 26S proteasomal degradation. If mis-
folded or unfolded proteins are not degraded by the protea-
some, they form aggregates and lead to the ER stress. The ER
stress triggers UPR to reduce the accumulation of unfolded
proteins and restore the ER function. When protein aggre-
gation or ER stress persists, the UPR signalling switches
from the pro-survival to pro-apoptotic. Consequently, the
26S proteasome complex also plays an important role in
regulation of the ER stress and cell survival. Therefore,
inhibition of the proteasomal function in cancer cells would
promote apoptosis and have an anti-tumour function. In fact,
the inhibition of the proteolytic activity of the 26S protea-
some has been shown to induce pro-apoptotic ER stress in
multiple myeloma [26], pancreatic [27], head and neck
cancer [7], and non-small cell lung carcinoma [28].
Fig. 6 Western immunoblot analysis of ORP150/GRP170 expression
in MDA-MB-231cells incubated with various concentrations of
bortezomib in normoxic (lanes 1–3) and hypoxic (lanes 4–6)
conditions for 12, 24 and 48 h. Lanes 1 and 4—without bortezomib,
lanes 2 and 5—with 25 nmol/l of bortezomib, lanes 3 and 6—with
50 nmol/l of bortezomib. Samples containing 20 lg of protein were
submitted to electrophoresis and immunoblotting. A representative
Western immunoblot is presented. The molecular mass (MM) of the
precision plus protein standards are indicated on the left side of the
lanes
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Proteasomal activity is essential for eliminating of
excess proteins and, by counteracting protein production,
establishing steady protein levels [29]. The ubiquitin–pro-
teasome pathway represents the major pathway for intra-
cellular protein degradation. The 26S proteasome is
responsible for the degradation of approximately 80 % of
cellular proteins, including misfolded and mutated proteins
as well as those involved in the regulation of development,
differentiation, cell proliferation, signal transduction,
apoptosis and antigen presentation [5]. Prolonged protea-
some inhibition induces stress responses that initiate
apoptosis via intrinsic pathway [29]. This is exploited
clinically in the treatment of multiple myeloma with the
proteasome inhibitor bortezomib. Inhibition of proteasome
activity by bortezomib is associated with an accumulation
and transcriptional induction of BH3-only proteins such as
PUMA, BIM, NOXA or BIK. BH3-only proteins antago-
nise antiapoptotic BCL-2 family members such as BCL-2,
BCL-xL or Mcl-1 and can activate the proapoptotic
members BAX and BAK [30]. Activated BAX and BAK
form pores in the outer mitochondrial membrane, resulting
in cytochrome c and activators of caspases (Smac/Diablo)
release from the intermembrane space into the cytosol.
This results in caspase-9 activation, inhibition of IAP
(inhibitor of apoptosis proteins), and subsequent apoptosis
execution by effector caspases [30]. Induction of NOXA
has been reported to be a key mechanism in bortezomib-
mediated apoptosis which is independent of P53 status but
dependent on c-Myc [31–34]. Bortezomib-mediated
apoptosis is accompanied by induction of c-Jun-NH2 ter-
minal kinase; generation of reactive oxygen species;
release of cytochrome c, the second mitochondria-derived
activator of caspases and apoptosis-inducing factor; and
activation of the intrinsic caspase-9 pathway and extrinsic
caspase-8 pathway [5].
In agreement with the cytoprotective role of molecular
chaperones it has been shown that they can prevent stress-
induced apoptosis [13, 14]. Overexpression of Hsp70 chap-
erons (ORP150 belongs to this family) prevents cytochrome
c release from mitochondria, blocks apoptosome formation
by binding to the apoptotic protease-activating factor (Apaf-
1), inhibits the release of apoptosis-inducing factor (AIF)
from mitochondria and prevents the loss of mitochondrial
transmembrane potential. The AIF released from mito-
chondria binds to Hsp70 and this interaction makes impos-
sible the nuclear import of AIF [15].
Senescence is thought to play an important role in
tumour suppression. Cellular senescence is more than just
replicative senescence. It is a common programme that is
activated by normal cells in response to various types of
stress. It has been named ‘stress-induced premature
senescence’ [19]. This type of senescence can act as a
tumour suppressor in order to prevent damaged cells to
multiply as well as a secondary outcome for cancer cells
due to therapeutic treatments [16]. Tumour suppressors
prevent cells from transforming into cancer by forming
molecular barriers for genomic instability and infinite
proliferation. They normally induce either apoptosis or a
permanent cell cycle arrest—senescence. Unfortunately,
which factors determine apoptosis or senescence are not
known at present [16].
Chaperones induction in cancer cells can lead to cancer
progression and may be a major cause of chemotherapeu-
tics resistance. It is one of the mechanisms protecting
cancer cells against entering the apoptotic pathway. Hence,
chaperone inhibition may be a promising tool to decrease
cytoprotection and to initiate apoptosis of cancer cells [16,
35]. Senescence and apoptosis normally counteract tumour
development and cancer cells must, therefore, overcome
these important tumour suppressor mechanisms to disrupt
this barrier. Senescence emerges as an important tumour
suppressor mechanism in vivo. Understanding and appli-
cation of cellular senescence and apoptosis for cancer
therapy has recently become a field of extensive research.
In conclusion, bortezomib represents compounds which
are able to induce apoptosis in human cancer cells in low
dose. We suggest that bortezomib may be candidates for
further evaluation as chemotherapeutic agents for human
breast cancer.
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